# Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

> **NCT06497530** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 30 (estimated)

## Conditions studied

- Extensive-Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Lurbinectedin
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT06497530
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06497530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06497530, "Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06497530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*